Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01685-x
Affiliations:
22
Authors:
25
Go to article
Institutions Authors Share
San Raffaele Scientific Institute, Italy
4.500000
 0.18
IRCCS San Raffaele Hospital (HSR), Italy
3.000000
 0.12
Vita-Salute San Raffaele University (UniSR), Italy
2.500000
 0.10
IRCCS Istituto Oncologico Veneto (IOV), Italy
2.000000
 0.08
Niguarda Hospital, Italy
2.000000
 0.08
University Hospital of Verona, Italy
1.500000
 0.06
IRCCS Mario Negri Institute, Italy
1.000000
 0.04
IRCCS Humanitas Research Hospital, Italy
1.000000
 0.04
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy
1.000000
 0.04
Azienda Ospedaliera Papa Giovanni XXIII, Italy
1.000000
 0.04
A.O. Ordine Mauriziano di Torino, Italy
1.000000
 0.04
George Papanicolaou General Hospital, Greece
1.000000
 0.04
University of Bologna (UNIBO), Italy
0.833333
 0.03
University of Verona (UNIVR), Italy
0.500000
 0.02
Sant'Orsola Malpighi Hospital, Italy
0.500000
 0.02
Azienda Universitario Ospedaliera di Cagliari, Italy
0.500000
 0.02
University of Cagliari (UNICA), Italy
0.500000
 0.02
GB Morgagni Hospital, Italy
0.333333
 0.01
Azienda Unità Sanitaria Locale della Romagna (AUSL Romagna), Italy
0.333333
 0.01
Interested in Oncology and Carcinogenesis?